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Abstract
Nanomaterials are being incorporated into many biological applications for use as therapeutics, sensors, or labels.
Silver nanomaterials are being utilized for biological implants and wound dressings as an antiviral material,
whereas gold nanomaterials are being used as biological labels or sensors due to their surface properties and
biocompatibility. Cytotoxicity data of these materials are becoming more prevalent; however, little research has
been performed to understand how the introduction of these materials into cells affects cellular processes. Here,
we demonstrate the impact that silver and gold nanoparticles have on cathepsin activity in vitro. Cathepsins are
important cellular proteases that are imperative for proper immune system function. We have selected to examine
gold and silver nanoparticles due to the increased use of these materials in biological applications. This manuscript
depicts how both of these types of nanomaterials affect cathepsin activity, which could impact the host’s immune
system and its ability to respond to pathogens. Cathepsin B activity decreases in a dose-dependent manner with
all nanoparticles tested. Alternatively, the impact of nanoparticles on cathepsin L activity depends greatly on the
type and size of the material.
Introduction
Cathepsins are lysosomal proteases that are present in
many different types of mammalian cells. Cathepsins B
and L are cysteine proteases localized in the lysosomes
and endosomes and are mainly involved in protein
degradation and antigen presentation [1]. Cathepsin B is
mainly expressed in antigen-presenting cells (APCs) and
is involved in protein processing for presentation and is
responsible for the degradation of the invariant chain
(Ii), a chaperone molecule essential for major histocom-
patibility complex (MHC) class II molecules assembly
and transport [2,3]. Cathepsin B also functions to pro-
cess MHC-II binding peptides in the endosome [3].
In addition to antigen presentation, cathepsin B is also
involved in many other physiological processes such as
inflammation, wound repair, apoptosis, and activation of
thyroxine and renin [2]. Cathepsin L is present in all
mammalian tissues and degrades both exogenous and
endogenous proteins [3]. Cathepsin L also regulates
MHC class II antigen presentation by cleaving Ii, espe-
cially in the thymic endothelium where it generates epi-
topes required for T-cell selection [3,4]. Due to the
many immune system processes that these enzymes reg-
ulate, alteration in their function could be detrimental
to the host.
Nanotechnology is a growing field of study focused on
the development of materials sized <100 nm. These
nano-sized particles exhibit unique physical and chemi-
cal properties that are often different than the bulk
material from which they are derived [5]. Nanomaterials
are being adapted for many uses, but until recently not
much effort has been put toward examining the biologi-
cal effects of these unique materials. Recent studies have
demonstrated that silver nanoparticles (Ag-NPs), which
are receiving considerable attention due to their anti-
microbial properties, are actually quiet toxic to mamma-
lian cells at low doses [6-8]. Bulk and nanosilver have
been shown to interact readily with mammalian proteins
and inactivate cellular enzymes, which could contribute
to Ag toxicity in vitro [9-11]. In this current study, we
examined the interaction of Ag-NPs with cathepsins
B and L and determined the extent of enzymatic
nhibition caused by the nano-Ag using both purified
cathepsins and a cell culture model. The effects of gold
* Correspondence: saber.hussain@wpafb.af.mil
1Applied Biotechnology Branch, Human Effectiveness Directorate, 711th
Human Performance Wing, Air Force Research Laboratory (711 HPW/RHPB),
Wright-Patterson Air Force Base (AFB), Area B, R ST, Bldg 837, Dayton,
OH 45433-5707, USA.
Full list of author information is available at the end of the article
Speshock et al. Nanoscale Res Lett 2011, 6:17
http://www.nanoscalereslett.com/content/6/1/17
© 2010 Speshock et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided
the original work is properly cited.nanoparticles (Au-NPs) on cathepsin activity were also
assessed due to recent concerns involving the effects of
cathepsin L on functionalized Au-NPs [12]. Au-NPs are
generally found to be non-toxic to mammalian cells in
culture [13], and there is little evidence indicating how
they interact with enzymes and whether they alter enzy-
matic function.
Materials and Methods
Nanoparticles
Plasma gas-synthesized 25-nm Ag-NPs were a kind gift
from Dr. Karl Martin (Novacentrix, Austin, TX). Colloi-
dal Ag-NPs at 10 nm and Au-NPs at 10 or 30 nm were
synthesized by Dr. Steven Oldenburg (NanoComposix,
San Diego, CA). Polysaccharide-coated Ag-NPs (PS-Ag)
10 and 25 nm were a generous gift from Dr. Dan Goia
(Clarkson University, Center for Advanced Materials
Processing, Potsdam, NY). These PS-Ag NPs were
synthesized by the reduction of Ag ions in solution by a
polysaccharide (acacia gum), which leads to a polysac-
charide surface coating [8]. All NPs were well character-
ized in our laboratory and were diluted in deionized
water to 1 mg/ml, sonicated with a probe sonicator, and
then further diluted in PBS or cell culture media.
Cell Line
Vero cells were obtained from the ATCC (CCL-81;
Manassas, VA). The Vero cells were maintained in
Dulbecco’s modified Eagle’sM e d i u m( D M E M ;
Biowhitaker, Basel, Switzerland) supplemented with
10% heat-inactivated fetal bovine serum (FBS; Gibco,
Carlsbad, CA) and 1% penicillin-streptomycin (PS;
Invitrogen, Carlsbad, CA).
Biocompatibility Assay
Vero cells were seeded into 96-well tissue culture-treated
plates at a concentration of 50,000 cells/well. Twenty-
four hours post-seeding, the Vero cells were exposed to
Ag- or Au-NPs. The NPs were diluted to the various
doses in DMEM + PS and sonicated for 30 s prior to
exposure. At 24-h post-exposure, a standard MTS assay
( P r o m e g a ,M a d i s o n ,W i s c o nsin) measuring mitochon-
drial function was performed to determine cell viability.
Cellular Cathepsin Activity Assay
Vero cells were treated with the above NPs at various
doses and were incubated for 24 h at 37°C in 5% CO2.
The NPs were removed and excess NPs were washed off
with PBS. CV-(RR)2 or CV-(FR)2 reagents were added to
the treated cells (diluted 1:250 in PBS) to detect changes
in cathepsin B or cathepsin L activity, respectively
(Biomol International, Plymouth Meeting, PA). Biomol’s
cathepsin detection kit utilizes the fluorophore,
cresyl violet (CV), linked to two peptides moieties
(arginine-arginine for cathepsin B and phenylalanine-
arginine for cathepsin L), which are cleaved when the
enzyme is active to release the fluorophore. The cathe-
psin substrate was incubated with the cells for 45 min at
37°C in 5% CO2 and was then read using a fluorometer
(BioTeck Synergy HT with Gen5 software) at excitation/
emission wavelengths of 594/625 nm. Alternatively for
the imaging, Hoechst (Molecular Probes – Invitrogen,
Carlsbad, CA) was added directly to the CV-(RR)2
or CV-(FR)2 reagents (1:1,000), and the cells
were imaged following the 45-min incubation with the
Becton Dickinson Pathway 435 spinning disc Confocal
microscope (BD, Franklin Lakes, NJ). The CV-(RR)2 or
CV-(FR)2 reagents were detected with a rhodamine filter
with settings normalized to the control (untreated) sample.
Purified Cathepsin Activity Assay
Purified cathepsins B and L were purchased from Bio-
mol International (SE198 and SE201, respectively).
Three micrograms of each protein was incubated with
the 4 types of Ag-NPs at either 10 or 50 μg/mL in
300 μLs t e r i l eH 2O for 1 h at room temperature with
rotation. Following this incubation, the mixture was
added in triplicate to a 96-well black-sided plate
(100 μL/well). Hundred microliters of the respective
Biomol CV reagent (diluted 1:125 in water) was then
added to each well of the enzyme-NP mixture. The
reaction was incubated for 45 min at 37°C in 5% CO2
and was then read in a fluorometer. The process was
repeated to obtain a total of six replicates.
Statistical Analysis
Data were expressed as the mean ± standard error of
the mean (SEM). The one-way ANOVA (Prism 5 statis-
tical and graphing software; GraphPad Software, Inc, La
Jolla, CA) was used for the data analysis. The one-way
ANOVA was used to determine the effect of test com-
pound concentration on the mean number of treat-
ments/well. P ≤ 0.05 was used as the level for
significance.
Results
Ag-NP Biocompatibility in Vero cells
After a 24-h exposure, a 25% decline in cell viability was
observed in Vero cells exposed to 50 μg/ml of 10-nm
uncoated Ag-NPs (Figure 1). Treatments with 10-nm
uncoated Ag-NPs at 75 and 100 μg/ml resulted in a 60%
reduction in cell viability (Figure 1). There was no further
reduction in cell viability in the 50 μg/ml dose, but the
cells treated with 75–100 μg/ml died off by day 2 (data not
shown). Concentrations of uncoated 10-nm Ag-NPs
lower than 50 μg/ml had little effect on Vero cell viability
(Figure 1). The 10-nm PS-Ag had no significant effects on
the Vero cells in the first 24 h (Figure 1), but the 75 and
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after 48 h (data not shown), suggesting an instability of the
coating. The concentrations of Ag-PS 10 nm at 50 μg/ml
or less had no effect on cell viability at later time points
(data not shown). There was little cytotoxicity observed in
Vero cells treated with the uncoated or polysaccharide-
coated 25-nm Ag-NPs (Figure 1).
Cathepsin B Activity in Ag-NP-treated Cells
A significant decrease in red fluorescent intensity, indi-
cating a decrease in cathepsin B activity, was observed
in the 50 μg/ml doses of 10 nm both uncoated and PS-
coated and 25-nm uncoated Ag-NPs (Figure 2d, f, h)
over the untreated control (Figure 2b). There was little
visual difference in red fluorescence intensity between
the 10 μg / m lt r e a t e dg r o u p s( F i g u r e2 c ,e ,g ,i )a n dt h e
25-nm PS-Ag at 50 μg/ml (Figure 2j) from the untreated
control (Figure 2b), although the 10-nm PS-Ag and
25-nm uncoated Ag-NPs did have a significant decline
in fluorescence intensity (Figure 2 table). The decrease
in cathepsin B activity in Vero cells treated with Ag-NPs
was confirmed via fluorescent quantification in a fluor-
escent plate reader and a dose-dependent decrease in
cathepsin B activity is observed in all treatment groups
except for the 25-nm PS-Ag, which interestingly had no
effect on cathepsin B activity (Figure 2 table).
Cathepsin L Activity in Ag-NP-treated Cells
Cathepsin L activity appears to be more sensitive to
Ag-NP exposure. All 4 types of Ag-NPs tested demon-
strated a significant reduction of cathepsin L activity in
Vero cells (Figure 3). Minimal cathepsin L activity was
observed when the cells were treated with any of the
Ag-NPs at 50 μg/ml (Figure 3d, f, h, j), and this decrease
was determined by quantitative assessment to be statisti-
cally significant (Figure 3 table). There was little discern-
able difference in red fluorescence between the 10 μg/ml
uncoated Ag-NP-treated cells (Figure 3c, g) versus the
Figure 1 Biocompatibility of Ag-NPs in Vero cells. Cytotoxic
levels were determined for uncoated and polysaccharide-coated 10
and 25-nm Ag-NPs, following a 24-h exposure using a standard MTS
cell viability assay. The cell viability in the treatment groups is
expressed as percent control and plotted as the mean +/- standard
error of the mean (SEM). (n = 8).
Figure 2 Cathepsin B confocal imaging in Ag-NP-treated Vero cells. A fluorescent substrate cleaved by active cathepsin B was detected
using confocal microscopy in Vero cells treated with Ag-NPs or left untreated. a Negative control (Vero cells alone), b Positive control (Vero
cells + CV-(FR)2), c 10-nm uncoated Ag-NP 10 μg/ml, d 10-nm uncoated Ag-NP 50 μg/ml, e 10-nm PS-Ag-NP 10 μg/ml, f 10-nm PS-Ag-NP
50 μg/ml, g 25-nm uncoated Ag-NP 10 μg/ml, h 25-nm uncoated Ag-NP 50 μg/ml, i 25-nm PS-Ag-NP 10 μg/ml, j 25-nm PS-Ag-NP 50 μg/ml.
Red fluorescent intensity was normalized to Vero cells exposed to the substrate (b). The table below represents a quantitative assessment of the
confocal images as determined using a fluorescent plate reader. The values indicate the mean percent of control +/- SEM (n = 6).
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(10 and 25 nm) appear to cause a slight, yet significant
decline in cathepsin L activity at this dose (Figure 3e, i,
table). The decrease in cathepsin L enzymatic activity
caused by Ag-NPs was much greater than that observed
with cathepsin B (Figures 2, 3).
Effects of Ag-NPs on Purified Cathepsins
To determine whether the Ag-NPs were influencing the
cell signaling or the enzyme directly, the Ag-NPs were
also incubated with purified cathepsin B or L, which
were then assayed for activity. A significant decrease
was seen in the activity of the purified cathepsin B
enzyme with the 10-nm Ag-NPs at 10 μg/ml and even
greater at 50 μg/ml, regardless of the presence or
absence of the PS coating (Figure 4a). The 25-nm
uncoated Ag-NPs had little effect on cathepsin B activity
at 10 μg/ml, but exhibited similar affects as the 10-nm
particles at a dose of 50 μg/ml (Figure 4a). The 25-nm
PS-Ag displayed a similar effect as the 25-nm uncoated
Ag-NP, with no effect at 10 μg/ml and a significant
decrease in cathepsin B activity at 50 μg/ml, however,
the decrease with this particle was much less than that
with the uncoated 25-nm Ag-NP (Figure 4a). When the
purified cathepsin L enzyme was treated with Ag-NPs,
the effect on activity was also much more significant
than the effect on purified cathepsin B (Figure 4). All
four Ag-NPs tested caused a significant decrease in
cathepsin L activity at both the 10 and 50 μg/ml doses,
with the 10-nm Ag-NPs (uncoated and PS-coated) caus-
ing a more pronounced effect (Figure 4b).
Au-NP Biocompatibility in Vero Cells
The Au-NPs at 10 and 30 nm had minimal effects on
the viability of Vero cells in culture (Figure 5). There
was a slight decrease in the mitochondrial function of
the Vero cells treated with very low (5 μg/ml) or very
high (100 μg/ml) doses of Au-NP 10 (Figure 5), but a
recovery was made by the cells following a 48-h expo-
sure (data not shown).
Au-NP effects on Cathepsin Activity
After a 24-h exposure of Vero cells to Au-NPs, a slight
decrease in cathepsin B activity was observed in cells
treated with either 10- or 30-nm Au-NPs at doses of
5–25 μg/ml (Figure 6a). A more significant decrease in
cathepsin B activity was observed when the Vero cells
were exposed to higher doses of these NPs (Figure 6a).
Conversely, the low doses of 10- and 30-nm Au-NPs
actually had a stimulatory effect on cathepsin L activity
(Figure 6b). At concentrations of 1–10 μg/ml of the
10-nm particles and 5–50 μg/ml of the 30-nm particles,
a significant upregulation of cathepsin L was observed
in Vero cells (Figure 6b). A significant decrease in cathe-
psin L activity was finally observed at 50–100 μg/ml of
the 10-nm Au-NP, but no decrease was ever seen in
Vero cells treated with 30-nm Au-NPs (Figure 6b).
Interestingly, incubation of the Au-NPs with the purified
Figure 3 Cathepsin L confocal imaging in Ag-NP-treated Vero cells. A fluorescent substrate cleaved by active cathepsin L was detected
using confocal microscopy in Vero cells treated with Ag-NPs or left untreated. a Negative control (Vero cells alone), b Positive control (Vero
cells + CV-(FR)2), c 10-nm uncoated Ag-NP 10 μg/ml, d 10-nm uncoated Ag-NP 50 μg/ml, (e) 10-nm PS-Ag-NP 10 μg/ml, f 10-nm PS-Ag-NP
50 μg/ml, g 25-nm uncoated Ag-NP 10 μg/ml, h 25-nm uncoated Ag-NP 50 μg/ml, i 25-nm PS-Ag-NP 10 μg/ml, j 25-nm PS-Ag-NP 50 μg/ml.
Red fluorescent intensity was normalized to Vero cells exposed to the substrate (b). The table below represents a quantitative assessment of the
confocal images as determined using a fluorescent plate reader. The values indicate the mean percent of control +/- SEM (n = 6).
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ity of either cathepsin B or L at 10 μg/ml (Figure 6c, d),
and although there was a significant decrease in the
50 μg/ml dose of Au-NPs (Figure 6c, d), the decline in
cathepsin activity with these NPs was not as dramatic as
that observed with theA g - N P s( F i g u r e4 ) .
Discussion
The research illustrated here demonstrates the effects
of Ag- and Au-NPs on cathepsin enzymatic function.
We have shown that Ag-NPs decrease the efficiency
of cathepsin cleavage in a dose-dependent manner
with significant effects observed at doses as low as
1–5 μg/ml, which is non-toxic to the cell itself. The
inhibitory effects of the NPs on cathepsin activity
were observed within as little as 1 h of incubation
(data not shown); following 24 h of incubation with
the NPs, the cathepsin activity was significantly
affected in Vero cells. The Ag-NPs had a greater
effect against the activity of purified cathepsins than
that of Vero cell cathepsins. This may suggest a possi-
ble direct interaction of theA g - N P sw i t ht h ep r o t e i n s ;
however, the internalized Ag-NPs are likely to inter-
act with many proteins in the cell and not just the
cathepsins, therefore diluting the dose actually
exposed to the cathepsins themselves, which could
also account for this difference. Bulk silver and
Ag-NPs have previously been shown to inhibit the
sodium-potassium ATPase [9,10] and FYN kinase
[11], respectively, indicating that Ag inhibits different
types of enzymatic function, which should be consid-
ered prior to use in living systems. Au-NPs also
inhibited cathepsin B activity both in a cellular model
and with the purified enzyme. However, even more
interesting was the impact of Au-NPs on cathepsin L
activity. When the Vero cells were exposed to
Au-NPs, a stimulatory effect of cathepsin L activity
was observed. Conversely, a decline in cathepsin L
activity was observed when the Au-NPs were incu-
bated with the purified enzyme. This may indicate
that the Au-NPs are interacting with the cathepsins
indirectly, possibly through a signaling cascade, inside
of the cells.
The biological applications of both Au- and Ag-NPs
are very promising, but little effort has been put into
determining how they may affect the natural function of
the cells in which they are incorporated. Both Ag- and
Au-NPs are capable of recognizing and readily binding
thiol groups of proteins and other ligands, suggesting
that they would likely have similar effects on protein
activity [14,15]. However, the two types of nanomaterials
Figure 5 Biocompatibility of Au-NPs in Vero cells. Cytotoxic
levels were determined for 10- and 30-nm Au-NPs, following a 24-h
exposure using a standard MTS cell viability assay. The cell viability
in the treatment groups is expressed as percent control and plotted
as the mean +/- SEM (n = 8).
Figure 4 Ag-NP effects on purified cathepsin B and L enzymes.
Ag-NPs were incubated with purified cathepsin B (a)o rL( b)
enzymes. The amount of cathepsin activity in the treatment groups
is expressed as percent control and plotted as the mean +/- SEM.
Fluorescence was determined using a fluorescent plate reader
(*P < 0.05, n = 6).
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A u - N P sa r ec o n s i d e r e dt ob er e l a t i v e l yb e n i g nt om o s t
cells, which make them an attractive tool for biomedical
applications [13]. Conversely, Ag-NPs have been shown
to be toxic to cell lines at low concentrations [8] and
appear to have a more significant affect on altering
enzymatic activity.
Biological molecules are being added to Au- and
Ag-NPs to improve their biocompatibility or functional-
ity for biological applications. However, recently, it was
determined that cathepsin L can cleave biological
moieties off functionalized nanoparticles [12]. See et al
utilized functionalized gold nanoparticles to assess the
ability of cathepsin L to cleave substrates off the NPs
and confirmed that upon internalization into the cell,
the substrate is cleaved off the Au-NPs by cathepsin L
[12]. We utilized similar sized Au-NPs and Ag-NPs to
determine the effects of these NPs on cathepsin activity.
We concluded that the Au-NPs, but not the Ag-NPs,
stimulated cathepsin L activity in cells, confirming that
functional groups added to the surface of Au-NPs may
be lost upon cell internalization. Alternatively, cathepsin
B activity was decreased by both types of NPs testing,
indicating that cathepsin B directed cleavage of biomole-
cules will be inhibited in the presence of NPs. Our
findings suggest that the use of cathepsin L inhibitors or
alternate core metals may be necessary for use of intra-
cellular nano-based therapeutics and sensors.
Cathepsin activity is important for many cellular pro-
cesses, most notably for priming of the adaptive
immune response through antigen processing [16].
Therefore, using materials that are capable of inhibiting
cathepsin activity for biological applications may per-
haps cause harmful side-effects. Studies have suggested
the potential for Ag-NPs as an antimicrobial: however, if
they cause a dramatic reduction in cellular cathepsin
activity, which can alter the adaptive immune response,
they may actually interfere with the host’s ability to
clear the infection. There are a lot of beneficial biomedi-
cal applications for using nanomaterials, but careful con-
sideration to avoid potential undesired effects must be
determined before they are used in vivo.
Figure 6 Quantitative assessment of cathepsin activity following Au-NP exposure. A fluorescent substrate was processed by cathepsin B
(a) or cathepsin L (b) in Vero cells or purified cathepsin B (c)o rL( d) treated with Au-NPs or left untreated. The fluorescence released following
proteolytic cleavage of the substrate was determined using a fluorescent plate reader. The amount of cathepsin activity in the treatment groups
is expressed as percent control and plotted as the mean +/- SEM. (*P < 0.05 significantly reduced, #P < 0.05 significantly increased; n = 6).
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